Data / Research funding / Iowa / Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc.: 5 NIH awards ($6.3M), fiscal years 2021 to 2026
Viewpoint Molecular Targeting, Inc. in Coralville, IA is funded under 5 NIH awards ($6.3M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- RDZCK3F6AU73
- State
- Iowa
Awards
5 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Image-guided dosimetry-based alpha particle therapy for neuroblastoma. | NIH | National Cancer Institute | 2022 to 2023 | $1,951,675 | August 4, 2022 | July 31, 2025 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma | NIH | National Cancer Institute | 2022 to 2023 | $1,924,767 | June 1, 2019 | May 31, 2025 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma. | NIH | National Cancer Institute | 2021 | $999,883 | September 7, 2020 | August 31, 2022 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors. | NIH | National Cancer Institute | 2021 | $998,648 | September 15, 2020 | August 31, 2022 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| Antibody-based prertargeted alpha particle therapy for ovarian cancer | NIH | National Cancer Institute | 2024 | $391,553 | June 5, 2024 | November 30, 2025 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2024 | 1 | $391,553 | 0 | $0 |
| 2023 | 2 | $1,909,549 | 0 | $0 |
| 2022 | 2 | $1,966,893 | 0 | $0 |
| 2021 | 2 | $1,998,531 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.395 | November 2, 2026 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) | PAR-26-152 | NIH | 93.395 | November 11, 2026 | Not listed | Same assistance listing 93.395 as 5 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.395 | November 20, 2026 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.395 | January 7, 2027 | $375,000 | Same assistance listing 93.395 as 5 awards here |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | PAR-25-079 | NIH | 93.395 | January 7, 2027 | $500,000 | Same assistance listing 93.395 as 5 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.395 | January 7, 2027 | $499,999 | Same assistance listing 93.395 as 5 awards here |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) | RFA-CA-27-005 | NIH | 93.395 | January 11, 2027 | $700,000 | Same assistance listing 93.395 as 5 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) | RFA-CA-26-010 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) | RFA-CA-27-003 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.395 | April 5, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.395 | April 5, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.395 | June 11, 2027 | $600,000 | Same assistance listing 93.395 as 5 awards here |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | 93.395 | July 12, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.395 | July 17, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | 93.395 | September 7, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | PAR-24-325 | NIH | 93.395 | September 7, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.395 | October 4, 2027 | Not listed | Same assistance listing 93.395 as 5 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.395 | October 19, 2027 | $300,000 | Same assistance listing 93.395 as 5 awards here |
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) | PAR-27-078 | NIH | 93.395 | October 25, 2027 | $375,000 | Same assistance listing 93.395 as 5 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.